Dezhan Healthcare
Market Cap
CN¥9.4b
Last Updated
2021/04/11 09:20 UTC
Data Sources
Company Financials
Executive Summary
Dezhan Healthcare Company Limited researches and develops, manufactures, and sells pharmaceutical products for cardiovascular and cerebrovascular diseases. More Details
Snowflake Analysis
Flawless balance sheet and overvalued.
Share Price & News
How has Dezhan Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 000813 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 000813's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
5.8%
813
-0.1%
CN Pharmaceuticals
-1.1%
CN Market
1 Year Return
-23.6%
813
15.8%
CN Pharmaceuticals
28.4%
CN Market
Return vs Industry: 000813 underperformed the CN Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: 000813 underperformed the CN Market which returned 28.4% over the past year.
Shareholder returns
| 813 | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.8% | -0.1% | -1.1% |
| 30 Day | 1.7% | 3.9% | 1.0% |
| 90 Day | 4.7% | -5.4% | -5.8% |
| 1 Year | -23.6%-23.6% | 16.9%15.8% | 30.4%28.4% |
| 3 Year | -55.3%-55.3% | 25.2%20.7% | 25.9%19.9% |
| 5 Year | n/a | 41.6%34.1% | 23.6%15.5% |
Long-Term Price Volatility Vs. Market
How volatile is Dezhan Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Dezhan Healthcare undervalued compared to its fair value and its price relative to the market?
39.32x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 000813 (CN¥4.22) is trading above our estimate of fair value (CN¥2.57)
Significantly Below Fair Value: 000813 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 000813 is poor value based on its PE Ratio (39.3x) compared to the CN Pharmaceuticals industry average (31.2x).
PE vs Market: 000813 is poor value based on its PE Ratio (39.3x) compared to the CN market (33.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 000813's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 000813 is good value based on its PB Ratio (1.6x) compared to the CN Pharmaceuticals industry average (2.7x).
Future Growth
How is Dezhan Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
24.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dezhan Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Dezhan Healthcare performed over the past 5 years?
-13.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 000813 has high quality earnings.
Growing Profit Margin: 000813's current net profit margins (19.7%) are lower than last year (26.2%).
Past Earnings Growth Analysis
Earnings Trend: 000813's earnings have declined by 13.1% per year over the past 5 years.
Accelerating Growth: 000813's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000813 had negative earnings growth (-55.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.8%).
Return on Equity
High ROE: 000813's Return on Equity (4%) is considered low.
Financial Health
How is Dezhan Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: 000813's short term assets (CN¥4.3B) exceed its short term liabilities (CN¥758.9M).
Long Term Liabilities: 000813's short term assets (CN¥4.3B) exceed its long term liabilities (CN¥35.8M).
Debt to Equity History and Analysis
Debt Level: 000813's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: 000813's debt to equity ratio has reduced from 10.6% to 0.3% over the past 5 years.
Debt Coverage: 000813's debt is well covered by operating cash flow (4858%).
Interest Coverage: 000813 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Dezhan Healthcare current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 000813's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 000813's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 000813's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 000813's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 000813's dividend in 3 years as they are not forecast to pay a notable one for the CN market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Dezhan Healthcare has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Dezhan Healthcare Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Dezhan Healthcare Company Limited
- Ticker: 813
- Exchange: SZSE
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥9.359b
- Shares outstanding: 2.22b
- Website: https://www.jarlin.com.cn
Number of Employees
Location
- Dezhan Healthcare Company Limited
- Shuangqiao East Road
- Chaoyang District
- Beijing
- China
Listings
Biography
Dezhan Healthcare Company Limited researches and develops, manufactures, and sells pharmaceutical products for cardiovascular and cerebrovascular diseases. The company is based in Beijing, China.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 09:20 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.